Last updated: February 27, 2026
What is the drug identified by NDC 00378-8020?
NDC 00378-8020 corresponds to Xyrem (sodium oxybate). It is primarily used to treat narcolepsy with cataplexy and hypersomnia. The drug is marketed by Jazz Pharmaceuticals. Its formulation involves a high-strength oral solution.
Market Overview
Market Size and Patient Population
- U.S. narcolepsy prevalence approximates 135,000 reported cases, with roughly 25% experiencing cataplexy [1].
- Estimated annual treatment population: 33,750 patients (25% of total narcolepsy cases).
- These figures exclude off-label uses and off-brand treatments.
Competitive Landscape
| Product |
Manufacturer |
Indications |
Annual Market Size (USD) |
Notes |
| Xyrem (sodium oxybate) |
Jazz Pharmaceuticals |
Narcolepsy, cataplexy |
Approx. $1.5 billion |
Dominant in narcolepsy space |
| Sunosi (solriamfetol) |
Jazz Pharmaceuticals |
Excessive sleepiness |
$150 million |
Approved for narcolepsy/hypersomnia |
| Off-label therapies |
Multiple |
Sleep disorders |
Varies |
Includes modafinil, sodium oxybate off-label |
Market Trends and Dynamics
- Growing diagnosis rates: Advances in sleep disorder diagnostics raise treatment numbers.
- Patent expiration concerns: The primary patent for Xyrem expired in 2011; current patents protect formulations and delivery methods.
- Generic entry: No authorized generics have entered the U.S. market as of 2023; however, multiple competing medications are available.
Regulatory and Patent Status
- The original patent on Xyrem expired in 2011, but composition-of-matter patents relevant to specific formulations remain active through patents expiring in the early 2030s.
- Drug exclusivity was extended through orphan drug designation, maintaining market exclusivity until at least 2025 for certain formulations.
- U.S. FDA approval date: November 2002.
Price Analysis and Projections
Current Pricing
- Wholesale acquisition cost (WAC) for Xyrem: approximately $50 per mL.
- Typical monthly treatment costs range from $25,000 to $45,000 depending on dosage and insurance coverage.
- Medicare and commercial insurers negotiate prices, but actual patient out-of-pocket varies.
Price Trends (2018–2023)
- Prices for Xyrem have remained relatively stable over the years, with slight increases averaging around 2-3% annually.
- No significant discounts or rebates data publicly available; industry estimates suggest rebates reduce sale prices by approximately 20%.
Future Price Projections
| Year |
Projected Price Range (per mL) |
Assumptions |
| 2024 |
$52–$55 |
Continued market stability; potential generic entry delayed |
| 2025 |
$55–$58 |
Patent protections maintained; competition remains limited |
| 2026 |
$58–$62 |
Possible introduction of biosimilar or generic versions |
| 2027+ |
$60–$65 |
Entry of generics could compress prices but likely with limited impact due to patent protections |
Impact of Patent Expiry and Generics
- Patent expiration slated for 2031 to 2033; generic competition could lead to price drops of 20-40% upon market entry.
- Biosimilar or alternative formulations could further modulate prices.
Distribution and Access Factors
- Insurance coverage significantly influences patient costs.
- Formulary restrictions may limit access, especially for off-label indications.
- Pricing negotiations increasingly focus on value-based arrangements with payers.
Key Considerations for Stakeholders
- Pharmacoeconomic evaluations will influence future adoption.
- Market entry timing for generics remains uncertain; patent defense strategies may extend exclusivity.
- Acceleration in diagnosis rates could expand market size, impacting pricing sustainability.
Key Takeaways
- Xyrem (NDC 00378-8020) dominates the narcolepsy treatment segment with recent stable pricing.
- The U.S. narcolepsy patient base is approximately 135,000, with drivers including increased diagnosis.
- Price projections suggest modest annual increases, with potential significant declines upon patent expiry around 2031–2033.
- Market dynamics are influenced by patent status, off-label use, insurance negotiations, and emerging competitive therapies.
- Stakeholders should monitor patent protections, regulatory developments, and market entry strategies to inform investment and R&D decisions.
FAQs
Q1: When is generic competition expected for Xyrem?
A1: Patent protections are set to expire between 2031 and 2033, potentially enabling generic entry.
Q2: What is the primary driver of Xyrem's high treatment cost?
A2: Limited competition and high dosage requirements contribute to pricing; manufacturing costs are relatively low.
Q3: How does Xyrem compare to alternative narcolepsy treatments?
A3: Xyrem remains the most effective for cataplexy and hypersomnia, but newer therapies such as Sunosi offer alternative options at lower costs.
Q4: What factors could impact future pricing?
A4: Patent expiration, biosimilar/generic entry, insurance reimbursement policies, and clinical guideline updates.
Q5: Are there regulatory risks affecting Xyrem’s market?
A5: Regulatory scrutiny on abuse potential and off-label use may influence prescribing patterns, but current approvals are stable.
References
[1] National Sleep Foundation. (2021). Narcolepsy prevalence data. Retrieved from https://sleepfoundation.org/narcolepsy-prevalence
